Patents by Inventor Mi SHEN

Mi SHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11585816
    Abstract: An automated method and system for determining the risk of developing a cancer in a subject, the method comprising preparing a tissue sample obtained from the subject for visually identifying at least one biological marker associated with the cancer, digitally scanning the prepared tissue sample, analyzing the scanned image of the tissue sample to identify regions of interest, quantifying at least one parameter associated with the marker, and executing an algorithm using the quantified parameter to calculate a risk score, wherein the risk score is representative of the risk of the individual developing the cancer.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: February 21, 2023
    Assignee: Proteocyte Diagnostics Inc.
    Inventors: Ying Gu, Jason T. K. Hwang, Kenneth P. H. Pritzker, Ranju Ralhan, Mi Shen
  • Patent number: 11110202
    Abstract: A differential tissue-engineered nerve including motor-like nerves and sensory-like nerves. The motor-like nerve and the sensory-like nerve respectively includes a motor-like nerve outer tube and a motor-like nerve fiber in the outer tube as well as a sensory-like nerve outer tube and a sensory-like nerve fiber in the outer tube. Schwann cells and/or fibroblasts derived from motor nerves and sensory nerves are respectively contained in surfaces or pores of the motor-like and sensory-like nerve outer tubes. Transsynaptic signal molecules Neuroligin-1 and Neuroligin-2 are contained in surfaces or pores of the motor-like and sensory-like nerve fibers. Neuroligin-1 is selectively used to specifically promote synaptic remodeling of motor neurons, while Neuroligin-2 is selectively used to specifically promote synaptic remodeling of sensory neurons, so that repair efficiency of motor nerve cells and sensory nerve cells is improved.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: September 7, 2021
    Assignee: NANTONG UNIVERSITY
    Inventors: Xin Tang, Cheng Sun, Gang Chen, Xiaosong Gu, Yumin Yang, Fei Ding, Yanpei Gong, Qianru He, Hongkui Wang, Mi Shen
  • Publication number: 20210268149
    Abstract: A differential tissue-engineered nerve including motor-like nerves and sensory-like nerves. The motor-like nerve and the sensory-like nerve respectively includes a motor-like nerve outer tube and a motor-like nerve fiber in the outer tube as well as a sensory-like nerve outer tube and a sensory-like nerve fiber in the outer tube. Schwann cells and/or fibroblasts derived from motor nerves and sensory nerves are respectively contained in surfaces or pores of the motor-like and sensory-like nerve outer tubes. Transsynaptic signal molecules Neuroligin-1 and Neuroligin-2 are contained in surfaces or pores of the motor-like and sensory-like nerve fibers. Neuroligin-1 is selectively used to specifically promote synaptic remodeling of motor neurons, while Neuroligin-2 is selectively used to specifically promote synaptic remodeling of sensory neurons, so that repair efficiency of motor nerve cells and sensory nerve cells is improved.
    Type: Application
    Filed: September 11, 2019
    Publication date: September 2, 2021
    Inventors: Xin TANG, Cheng SUN, Gang CHEN, Xiaosong GU, Yumin YANG, Fei DING, Yanpei GONG, Qianru HE, Hongkui WANG, Mi SHEN
  • Publication number: 20190072559
    Abstract: An automated method and system for determining the risk of developing a cancer in a subject, the method comprising preparing a tissue sample obtained from the subject for visually identifying at least one biological marker associated with the cancer, digitally scanning the prepared tissue sample, analyzing the scanned image of the tissue sample to identify regions of interest, quantifying at least one parameter associated with the marker, and executing an algorithm using the quantified parameter to calculate a risk score, wherein the risk score is representative of the risk of the individual developing the cancer.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 7, 2019
    Applicant: Proteocyte Diagnostics Inc.
    Inventors: Ying GU, Jason T.K. HWANG, Kenneth P.H. PRITZKER, Ranju RALHAN, Mi SHEN